drugset / Trial / NCT06959745
Magnesium-L-Threonate Improves Menopausal Symptoms
RandomizedParallel-groupSingle-blindTreatment
Summary
This trial has a randomized, single-blind, single-center, parallel-controlled design, with participant screening and trial implementation conducted at Guangdong Provincial People's Hospital. The study evaluate the efficacy of oral magnesium L-threonate supplementation on improving menopausal symptoms and quality of life among peri/post-menopausal women. This trial aims to explore whether oral magnesium L-threonate supplementation could alleviate menopausal syndromes. Participants will randomly assigned to conduct oral magnesium L-threonate supplementation or placebo for 8 weeks. Face-to-face and internet follow up will be conducted once per 2 weeks.
Timeline
- Start
- 2025-05-15
- Primary completion
- 2025-09-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Magnesium L-threonate | Unknown | 1740 mg | Oral |